Preclinical studies and clinical trials have demonstrated that SGLT2 inhibitors are associated with lower rates of decline in estimated glomerular filtration rate (eGFR), reduced proteinuria, and consequently, a slowing in DKD progression [7, 8]. Here, SLC5A2 is linked to diabetic kidney disease.